Idiosyncratic drug reactions: Past, present, and future

Chemical Research in Toxicology

Volumn 21, Issue 1, 2008, Pages 84-92

  Uetrecht, Jack ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALLOPURINOL; AMINOPHENAZONE; BIOLOGICAL MARKER; CARBAMAZEPINE; CLOZAPINE; DIHYDRALAZINE; HALOTHANE; ISONIAZID; NEVIRAPINE; PARACETAMOL; PENICILLIN G; PIPERANOMETOZINE; PROCAINAMIDE; RANITIDINE; TIENILIC ACID; TROGLITAZONE; VALPROIC ACID; XIMELAGATRAN;

AGRANULOCYTOSIS; CELL STRESS; COMPREHENSION; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; GENE; GENE EXPRESSION; GENETIC ANALYSIS; HLA SYSTEM; HUMAN; IMMUNE SYSTEM; INCIDENCE; LIVER FAILURE; LIVER TOXICITY; MEDICAL RESEARCH; METABOLITE; MORBIDITY; MORTALITY; NONHUMAN; PREDICTION; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; BIOTRANSFORMATION; DRUG INTERACTIONS; HAPTENS; HUMANS; INFLAMMATION; PHARMACEUTICAL PREPARATIONS;

ANIMALIA;

EID: 38949104743     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx700186p     Document Type: Review

References (70)

1. Uetrecht, J. (2007) Idiosyncratic drug reactions: Current understanding. Annu. Rev. Pharmacol. Toxicol. 47, 513-539.
2. Uetrecht, J. P. (1999) New concepts in immunology relevant to idiosyncratic drug reactions: The "danger hypothesis" and innate immune system. Chem. Res. Toxicol. 12, 387-395.
3. Landsteiner, K., and Jacobs, J. (1935) Studies on the sensitization of animals with simple chemical compounds. J. Exp. Med. 61, 643-656.
4. Parker, C. W., Deweck, A. L., Kern, M., and Eisen, H. N. (1962) The preparation and some properties of penicillenic acid derivatives relevant to penicillin hypersensitivity. J. Exp. Med. 115, 803-819.
5. Parker, C. W., and Thiel, J. A. (1963) Studies in human penicillin allergy: A comparison of various penicilloyl-polylysines. J. Lab. Clin. Med. 62, 482-491.
6. Moeschlin, S., and Wagner, K. (1952) Agranulocytosis due to the occurrence of leukocyte-agglutinins. Acta Haemat. 8, 29-41.
7. Uetrecht, J. P., Ma, H. M., MacKnight, E., and McClelland, R. (1995) Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis. Chem. Res. Toxicol. 8, 226-233.
8. Lecoeur, S., Andre, C., and Beaune, P. H. (1996) Tienilic acid-induced autoimmune hepatitis: Anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. Mol. Pharmacol. 50, 326-333.
9. Parker, C. W. (1982) Allergic reactions in man. Pharmacol. Rev. 34, 85-104.
10. Vergani, D., Mieli-Vergani, G., Alberti, A., Neuberger, J., Eddleston, A., Davis, M., and Williams, R. (1980) Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N. Engl. J. Med. 303, 66-71.
11. Warkentin, T. E. (2003) Heparin-induced thrombocytopenia: Pathogenesis and management. Br. J. Haematol. 121, 535-555.
12. Bourdi, M., Tinel, M., Beaune, P. H., and Pessayre, D. (1994) Interactions of dihydralazine with cytochromes P4501A: A possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol. Pharmacol. 45, 1287-1295.
13. Miller, E. C., and Miller, J. A. (1966) Mechanisms of chemical carcinogenesis: nature of proximate carcinogens and interactions with macromolecules. Pharmacol. Rev. 18, 805-838.
14. Mitchell, J. R., Jollow, D. J., Potter, W. Z., Davis, D. C., Gillette, J. R., and Brodie, B. B. (1973) Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther. 187, 185-194.
15. Park, B. K., Kitteringham, N. R., Maggs, J. L., Pirmohamed, M., and Williams, D. P. (2005) The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol. 45, 177-202.
16. Njoku, D., Laster, M. J., Gong, D. H., Eger, E. I., 2nd, Reed, G. F., and Martin, J. L. (1997) Biotransformation of halothane, enflurane, isoflurane, and desflurane to trifluoroacetylated liver proteins: Association between protein acylation and hepatic injury. Anesth. Analg. (Baltimore) 84, 173-178.
17. Martin, J. L., Kenna, J. G., Martin, B. M., Thomassen, D., Reed, G. F., and Pohl, L. R. (1993) Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase. Hepatology 18, 858-863.
18. Zimmerman, H. (1999) Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver, 2nd ed., Lippincott Williams & Wilkins, Philadelphia.
19. Zimmerman, H. J. (1976) Various forms of chemically induced liver injury and their detection by diagnostic procedures. Environ. Health Perspect. 15, 3-12.
20. Black, M., Mitchell, J. R., Zimmerman, H. J., Ishak, K. G., and Epler, G. R. (1975) Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69, 289-302.
21. Lewis, J. H., Zimmerman, H. J., Benson, G. D., and Ishak, K. G. (1984) Hepatic injury associated with ketoconazole therapy. Analysis of 33 cases. Gastroenterology 86, 503-513.
22. Murphy, E. J., Davern, T. J., Shakil, A. O., Shick, L., Masharani, U., Chow, H., Freise, C., Lee, W. M., and Bass, N. M. (2000) Troglitazone-induced fulminant hepatic failure. Acute Liver Failure Study Group. Dig. Dis. Sci. 45, 549-553.
23. Huang, Y. S., Chern, H. D., Su, W. J., Wu, J. C., Lai, S. L., Yang, S. Y., Chang, F. Y., and Lee, S. D. (2002) Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology 35, 883-889.
24. Vuilleumier, N., Rossier, M. F., Chiappe, A., Degoumois, F., Dayer, P., Mermillod, B., Nicod, L., Desmeules, J., and Hochstrasser, D. (2006) CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur. J. Clin. Pharmacol. 62, 423-129.
25. Bretscher, P., and Cohn, M. (1970) A theory of self-nonself discrimination. Science 169, 1042-1049.
26. Matzinger, P. (1994) Tolerance, danger and the extended family. Annu. Rev. Immunol. 12, 991-1045.
27. Fearon, D. T. (1997) Seeking wisdom in innate immunity [news; comment]. Nature 388, 323-324.
28. Matzinger, P. (2007) Friendly and dangerous signals: is the tissue in control? Nat. Immunol. 8, 11-13.
29. Seong, S. Y., and Matzinger, P. (2004) Hydrophobicity: An ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol. 4, 469-478.
30. Harris, H. E., and Raucci, A. (2006) Alarmin(g) news about danger: workshop on innate danger signals and HMGB1. EMBO Rep. 7, 774-778.
31. Seguin, B., and Uetrecht, J. (2003) The danger hypothesis applied to idiosyncratic drug reactions. Curr. Opin. Allergy Clin. Immunol. 3, 235-242.
32. Pichler, W. J. (2002) Pharmacological interaction of drugs with antigen-specific immune receptors: the p-i concept. Curr. Opin. Allergy Clin. Immunol. 2, 301-305.
33. Uetrecht, J. (2002) N-oxidation of drugs associated with idiosyncratic drug reactions. Drug Metab. Rev. 34, 651-665.
34. Lu, W., and Uetrecht, J. (2007) Possible bioactivation pathways of lamotrigine. Drug Metab. Dispos. 35, 1050-1056.
35. Kindmark, A., Jawaid, A., Harbron, C. G., Barratt, B. J., Bengtsson, O. F., Andersson, T. B., Carlsson, S., Cederbrant, K. E., Gibson, N. J., Armstrong, M., Lagerstrom-Fermer, M. E., Dellsen, A., Brown, E. M., Thornton, M., Dukes, C., Jenkins, S. C., Firth, M. A., Harrod, G. O., Pinel, T. H., Billing-Clason, S. M., Cardon, L. R., and March, R. E. (2007) Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J., in press.
36. Uetrecht, J. (2007) Idiosyncratic drug reactions: Current understanding. Annu. Rev. Pharmacol. Toxicol. 47,in press.
37. Warkentin, T. E., and Kelton, J. G. (2001) Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. 344, 1286-1292.
38. Maniratanachote, R., Shibata, A., Kaneko, S., Yamamori, I., Wakasugi, T., Sawazaki, T., Katoh, K., Tokudome, S., Nakajima, M., and Yokoi, T. (2005) Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. Toxicology 216, 15-23.
39. Ong, M. M., Latchoumycandane, C., and Boelsterli, U. A. (2007) Troglitazone-induced hepatic necrosis in an animal model of silent genetic mitochondrial abnormalities. Toxicol. Sci. 97, 205-213.
40. Pessayre, D., Mansouri, A., Haouzi, D., and Fromenty, B. (1999) Hepatotoxicity due to mitochondrial dysfunction. Cell Biol. Toxicol. 15, 367-373.
41. Guest, I., Sokoluk, B., MacCrimmon, J., and Uetrecht, J. (1998) Examination of possible toxic and immune mechanisms of clozapine-induced agranulocytosis. Toxicology 131, 53-65.
42. Roth, R. A., Luyendyk, J. P., Maddox, J. F., and Ganey, P. E. (2003) Inflammation and drug idiosyncrasy - Is there a connection? J. Pharmacol. Exp. Ther. 307, 1-8.
43. Leeder, J. S. (1998) Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs. Epilepsia 39, S8-S16.
44. Martin, A. M., Nolan, D., Gaudieri, S., Almeida, C. A., Nolan, R., James, I., Carvalho, F., Phillips, E., Christiansen, F. T., Purcell, A. W., McCluskey, J., and Mallal, S. (2004) Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl. Acad. Sci. U.S.A. 101, 4180-4185.
45. Chung, W. H., Hung, S. I., Hong, H. S., Hsih, M. S., Yang, L. C., Ho, H. C., Wu, J. Y., and Chen, Y. T. (2004) Medical genetics: A marker for Stevens-Johnson syndrome. Nature 428, 486.
46. Hung, S. I., Chung, W. H., Liou, L. B., Chu, C. C., Lin, M., Huang, H. P., Lin, Y. L., Lan, J. L., Yang, L. C., Hong, H. S., Chen, M. J., Lai, P. C., Wu, M. S., Chu, C. Y., Wang, K. H., Chen, C. H., Fann, C. S., Wu, J. Y., and Chen, Y. T. (2005) HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. U.S.A. 102, 4134-4139.
47. Lonjou, C., Thomas, L., Borot, N., Ledger, N., de Toma, C., Lelouet, H., Graf, E., Schumacher, M., Hovnanian, A., Mockenhaupt, M., and Roujeau, J. C. (2006) A marker for Stevens-Johnson syndrome . . .: Ethnicity matters. Pharmacogenomics J. 6, 265-268.
48. Pirmohamed, M., and Park, B. K. (2001) Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22, 298-305.
49. Bluestone, J. A., and Tang, Q. (2005) How do CD4+CD25+ regulatory T cells control autoimmunity? Curr. Opin. Immunol. 17, 638-642.
50. Liu, Z. X., Govindarajan, S., and Kaplowitz, N. (2004) Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology 127, 1760-1774.
51. Kensler, T. W., Wakabayashi, N., and Biswal, S. (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu. Rev. Pharmacol. Toxicol. 47, 89-116.
52. Okawa, H., Motohashi, H., Kobayashi, A., Aburatani, H., Kensler, T. W., and Yamamoto, M. (2006) Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem. Biophys. Res. Commun. 339, 79-88.
53. Qiu, Y., Benet, L. Z., and Burlingame, A. L. (1998) Identification of the hepatic protein targets of reactive metabolites of acetaminophen in vivo in mice using two-dimensional gel electrophoresis and mass spectrometry. J. Biol. Chem. 273, 17940-17953.
54. Myers, T. G., Dietz, E. C., Anderson, N. L., Khairallah, E. A., Cohen, S. D., and Nelson, S. D. (1995) A comparative study of mouse liver proteins arylated by reactive metabolites of acetaminophen and its nonhepatotoxic regioisomer, 3′-hydroxyacetanilide. Chem. Res. Toxicol. 8, 403-413.
55. Salminen, W. F., Jr., Voellmy, R., and Roberts, S. M. (1997) Differential heat shock protein induction by acetaminophen and a nonhepatotoxic regioisomer, 3′-hydroxyacetanilide, in mouse liver. J. Pharmacol. Exp. Ther. 282, 1533-1540.
56. Koen, Y. M., Yue, W., Galeva, N. A., Williams, T. D., and Hanzlik, R. P. (2006) Site-specific arylation of rat glutathione s-transferase A1 and A2 by bromobenzene metabolites in vivo. Chem. Res. Toxicol. 19, 1426-1434.
57. Gardner, I., Popovic, M., Zahid, N., and Uetrecht, J. P. (2005) A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo. Chem. Res. Toxicol. 18, 1384-1394.
58. Janeway, C., Travers, P., Walport, M., and Shlomchik, M. (2005) Immunobiology, 6th ed., Garland Science, New York.
59. Hopkins, J. E., Naisbitt, D. J., Kitteringham, N. R., Dearman, R. J., Kimber, I., and Park, B. K. (2005) Selective haptenation of cellular or extracellular protein by chemical allergens: Association with cytokine polarization. Chem. Res. Toxicol. 18, 375-381.
60. Evans, D. C., Watt, A. P., Nicoll-Griffith, D. A., and Baillie, T. A. (2004) Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development. Chem. Res. Toxicol. 17, 3-16.
61. Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., and Panoskaltsis, N. (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355, 1018-1028.
62. Leone, A. M., Kao, L. M., McMillian, M. K., Nie, A. Y., Parker, J. B., Kelley, M. F., Usuki, E., Parkinson, A., Lord, P. G., and Johnson, M. D. (2007) Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression. Chem. Res. Toxicol. 20, 600-608.
63. Dieckhaus, C., Miller, T., Sofia, R. D., and Macdonald, T. (2000) A mechanistic approach to understanding the species differences in felbamate bioactivation: relevance to drug-induced idiosyncratic reactions. Chem. Res. Toxicol. 28, 814-822.
64. Phillips, E. J. (2006) Genetic screening to prevent abacavir hypersensitivity reaction: Are we there yet? Clin. Infect. Dis. 43, 103-105.
65. Sayeh, E., and Uetrecht, J. P. (2001) Factors that modify penicillamine-induced autoimmunity in Brown Norway rats: Failure of the Th1/Th2 paradigm. Toxicology 163, 195-211.
66. Shenton, J. M., Popovic, M., Chen, J., Masson, M. J., and Uetrecht, J. P. (2005) Evidence of an immune-mediated mechanism for an idiosyncratic nevirapine-induced reaction in the female Brown Norway rat. Chem. Res. Toxicol. 18, 1799-1813.
67. Shenton, J. M., Teranishi, M., Abu-Asab, M. S., Yager, J. A., and Uetrecht, J. P. (2003) Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat. Chem. Res. Toxicol. 16, 1078-1089.
68. Bourdi, M., Eiras, D. P., Holt, M. P., Webster, M. R., Reilly, T. P., Welch, K. D., and Pohl, L. R. (2007) Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury. Chem. Res. Toxicol. 20, 208-216.
69. Ju, C. (2005) Immunological mechanisms of drug-induced liver injury. Curr. Opin. Drug Discovery Dev. 8, 38-13.
70. Hung, S. I., Chung, W. H., Jee, S. H., Chen, W. C., Chang, Y. T., Lee, W. R., Hu, S. L., Wu, M. T., Chen, G. S., Wong, T. W., Hsiao, P. F., Chen, W. H., Shih, H. Y., Fang, W. H., Wei, C. Y., Lou, Y. H., Huang, Y. L., Lin, J. J., and Chen, Y. T. (2006) Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 16, 297-306.